One-year Antibody Durability Induced by EuCorVac-19, a Liposome-Displayed COVID-19 RBD Subunit Vaccine, in Healthy Korean Subjects
Description
BACKGROUND: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization.
